AG
NKTR icon

Artal Group’s Nektar Therapeutics NKTR Stock Holding History

Artal Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-15,933
Closed -$5.54M – 149
2020
Q2 		$5.54M Buy
+15,933
New +$4.97M 0.15% 100
2019
Q4 		– Sell
-33,333
Closed -$9.67M – 104
2019
Q3 		$9.11M Sell
33,333
-13,334
-29% -$4.89M 0.37% 52
2019
Q2 		$24.9M Sell
46,667
-13,333
-22% -$6.69M 1.01% 24
2019
Q1 		$30.2M Buy
60,000
+6,667
+13% +$3.95M 1.23% 23
2018
Q4 		$26.3M Hold
53,333
– – 0.97% 24
2018
Q3 		$48.8M Sell
53,333
-6,667
-11% -$5.69M 1.27% 14
2018
Q2 		$43.9M Buy
60,000
+13,333
+29% +$15.4M 0.93% 16
2018
Q1 		$74.4M Buy
46,667
+20,000
+75% +$25.8M 0.93% 11
2017
Q4 		$23.9M Sell
26,667
-56,666
-68% -$33.5M 0.36% 25
2017
Q3 		$30M Sell
83,333
-10,000
-11% -$3.13M 0.52% 11
2017
Q2 		$27.4M Buy
93,333
+26,666
+40% +$7.71M 0.48% 17
2017
Q1 		$23.5M Hold
66,667
– – 0.52% 17
2016
Q4 		$12.3M Hold
66,667
– – 0.27% 31
2016
Q3 		$17.2M Sell
66,667
-26,666
-29% -$6.87M 0.34% 26
2016
Q2 		$19.9M Sell
93,333
-40,000
-30% -$8.94M 0.41% 15
2016
Q1 		$27.5M Buy
133,333
+26,666
+25% +$5.12M 0.54% 17
2015
Q4 		$27M Sell
106,667
-13,333
-11% -$2.74M 0.51% 23
2015
Q3 		$19.7M Buy
120,000
+6,667
+6% +$1.18M 0.44% 34
2015
Q2 		$21.3M Hold
113,333
– – 0.92% 33
2015
Q1 		$18.7M Buy
113,333
+3,333
+3% +$685K 0.86% 31
2014
Q4 		$25.6M Hold
110,000
– – 0.9% 24
2014
Q3 		$19.9M Buy
110,000
+20,000
+22% +$3.83M 0.73% 26
2014
Q2 		$17.3M Buy
90,000
+3,333
+4% +$589K 0.7% 30
2014
Q1 		$15.8M Sell
86,667
-20,000
-19% -$3.96M 0.57% 39
2013
Q4 		$18.2M Sell
106,667
-46,666
-30% -$7.53M 0.65% 29
2013
Q3 		$24M Sell
153,333
-13,334
-8% -$2.47M 0.78% 18
2013
Q2 		$28.9M Buy
+166,667
New +$25.6M 0.91% 14

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Artal Group's NKTR Position: Q3 2020 in Review

Artal Group sold out of Nektar Therapeutics (NKTR) in Q3 2020, closing a stake of 15,933 shares — an estimated $5.54M sold.

Artal Group first reported a position in NKTR in Q2 2013 and held it in 27 quarters. The position peaked at $74.4M in Q1 2018. 249 funds tracked by Wall St. Rank hold NKTR as of Q3 2020.

  • Artal Group reported no remaining Nektar Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Artal Group sold 15,933 Nektar Therapeutics shares in Q3 2020, an estimated $5.54M.
  • Artal Group first reported a position in Nektar Therapeutics in Q2 2013 and held it in 27 quarters.
  • Artal Group's Nektar Therapeutics position peaked at $74.4M in Q1 2018.
  • 249 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2020.

Based on Artal Group's 13F filing for Q3 2020, filed 13 Nov 2020.